Join @SSRaj017 today at #ASH25 for his session: “Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma” @ASH_hematology TODAY | 12 p.m. EST Learn more: https://t.co/qTM2rgBSkD

#ASH2025 second day! Two orals from our lab in the same session. In the first we define the concept of malignant transformation in SMM ( https://t.co/tSWRkfpxqb). Great collaboration with @MSKCancerCenter @MayoClinic @SylvesterCancer @MoffittNews @MDAndersonNews @LaStatale #mmsm

Join Dr. Xiaoli Mi this morning at #ASH25 for the presentation, "CAR T cells converge on a distinct transcriptional state over time in patients with diverse hematologic malignancies." #lymsm #leusm @MSKCancerCenter @ASH_hematology Learn more: https://t.co/BO7rCa4CTs

Join Dr. Lorenzo Falchi today at #ASH25 for his session: “Primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma.” @ASH_hematology TODAY | 10:15 a.m. EST Learn more:

📜 Led by @MilitSPatel and Dr @IMRTLee, out in @NatRevClinOncol today: 👉 We highlight the importance of #synergy between #human #care and #AI-informed #medicine for people with #cancer. 👉 AI can #augment human expertise, not replace it. 🔗 https://t.co/nzdwn7qalh

Join @UrviShahMD today at #ASH25 for her session: “Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial.” @ASH_hematology TODAY | 5:30 p.m. EST Learn more:

Oral Abstract 0250: @szusmani on KTX-1001 for heavily pre treated RRMM, 30% EMD, 30% HR, 40% w prior BCMA, 80% pent exposed, ⬇️ plt common AE, reasonable ORR in heavily treated pts w no viable options (slide 3) #ASH25 #MMSM @MSKCancerCenter #MeetUnmetNeed

Coming up at #ASH25: @sridevirajeeve will present a study evaluating remote patient monitoring for outpatient step-up dosing for bispecific antibodies at a large academic center. @MSKCancerCenter @ASH_hematology #mmsm Learn more: https://t.co/vV9j2gNFV3

Join @szusmani today at #ASH25 for his session: “Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma.” @ASH_hematology TODAY | 2:45 p.m. EST Learn more: https://t.co/roqF9RwirT

At #ASH25, Dr. Mohammad Alhomoud will present a study that determined the optimal fludarabine exposure in allogeneic hematopoietic cell transplantation recipients receiving post-transplant cyclophosphamide. @MSKCancerCenter @ASH_hematology Learn more: https://t.co/7bspTysE6L

Coming up at #ASH25: Dr. Xin Wang will present findings from a study that compared outcome disparities between Asian and White patients with newly diagnosed acute myeloid #leukemia. @MSKCancerCenter @ASH_hematology #leusm Learn more: https://t.co/znVZDNYCZa

At #ASH25, @kuokaichin will present a retrospective study that evaluated outcomes of patients with acute myeloid #leukemia whose cancer stopped responding to or returned after menin inhibitor treatment. #leusm @MSKCancerCenter @ASH_hematology Learn more: https://t.co/Wl1YghpcSW

#ASH25: Divyash Shah will present the results of a study assessing the comparative incidence of venous thromboembolism in patients with chemotherapy-induced thrombocytopenia treated with romiplostim. @MSKCancerCenter @ASH_hematology Learn more: https://t.co/9g7FGnRHkq

Hear Lauren Schaff, MD, of @MSKCancerCenter spotlight exciting data in leptomeningeal metastases presented by her colleague at #SNO2025 in the video below! 🧠👇 WATCH: https://t.co/vV0wTNRp33 @NeuroOnc #btsm

Tomorrow morning at #ASH25, Varun Iyengar, MD, will present a study evaluating venous thromboembolism risk factors found via genomic profiling cross subtypes of B-cell #lymphoma. @MSKCancerCenter @ASH_hematology #lymsm Learn more: https://t.co/cyQ6f4akmZ

At #ASH25, join @QuinlanSievers to learn about molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation. #lymsm @MSKCancerCenter @ASH_hematology TODAY | 4:32 p.m. ET Learn more: https://t.co/DsahRfcqiv

Can dietary changes delay progression from precursor disorders to a cancer - myeloma? Excited to share our manuscript is published online @CD_AACR @MSKCancerCenter @SanRaffaeleMI @Bellone_lab @DrMvandenBrink @LesokhinMD @Lauracgr001 @szusmani #mmsm #ASH25 https://t.co/nWvY90Azgr

At #ASH25, join @jzbos to learn how the cellular pathways that allow blood to clot can contribute to #cancer growth and spread, presenting opportunities for new treatment approaches. @MSKCancerCenter @ASH_hematology Learn more: https://t.co/RF7MJL2o4f

Researchers at MSK are contributing meaningful advancements to cancer care. New research from MSK finds a potential therapeutic opportunity in regulatory T cells’ resilience to the loss of #Foxp3; shows how cancer develops resistance to antibody-drug conjugates; and more:

Join @DrRichardJLin today at #ASH25 to learn about methods for preventing and treating age-related blood conditions, including #exercise, #nutrition, new therapies, and more. @MSKCancerCenter @ASH_hematology Learn more: https://t.co/gWoJIMS9Gz